{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics lance des essais cliniques en Europe pour les th\u00e9rapies de saut d&#039;exon 44 et d&#039;exon 45"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics a officiellement lanc\u00e9 des essais cliniques en Europe pour ses th\u00e9rapies innovantes de saut d&#039;exon ciblant l&#039;exon 44 et l&#039;exon 45, marquant une \u00e9tape importante dans le traitement de la dystrophie musculaire de Duchenne (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces th\u00e9rapies exp\u00e9rimentales visent \u00e0 traiter des mutations g\u00e9n\u00e9tiques sp\u00e9cifiques chez les patients atteints de DMD, dans le but de restaurer la production de dystrophine et d&#039;am\u00e9liorer les r\u00e9sultats cliniques. Le lancement de ces essais t\u00e9moigne de l&#039;engagement de Entrada \u00e0 faire progresser la m\u00e9decine g\u00e9n\u00e9tique de pr\u00e9cision et \u00e0 \u00e9largir l&#039;acc\u00e8s mondial \u00e0 de nouveaux traitements pour les maladies neuromusculaires rares. \u2013 En savoir plus\u00a0: <a href=\"https:\/\/dmdwarrior.com\/fr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">Qu\u2019est-ce que le saut d\u2019exon et comment fonctionne-t-il ?<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada Saut d&#039;exon 44 \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada Saut d&#039;exon 45 \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada Saut d&#039;exon 44 \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il s\u2019agit d\u2019une \u00e9tude du m\u00e9dicament exp\u00e9rimental ENTR-601-44 chez des participants atteints de dystrophie musculaire de Duchenne (DMD), une maladie g\u00e9n\u00e9tique rare.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacements<\/strong>:Belgique, Italie, Espagne, Royaume-Uni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 4 ans \u00e0 20 ans (enfant, adulte)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada Saut d&#039;exon 45 \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il s\u2019agit d\u2019une \u00e9tude du m\u00e9dicament exp\u00e9rimental ENTR-601-45 chez des participants atteints de dystrophie musculaire de Duchenne (DMD), une maladie g\u00e9n\u00e9tique rare.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacements<\/strong>:Belgique, Italie, Pays-Bas, Espagne, Royaume-Uni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 4 ans \u00e0 20 ans (enfant, adulte)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/fr\/tag\/entrada-therapeutics\/\">En savoir plus sur Entrada Therapeutics<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}